Brief: Vaxxinity Doses First Subjects In Phase 1 Clinical Trial Of UB-313
13/09/2022 15:08
Sept 13 (Reuters) - Vaxxinity Inc VAXX.O :
* VAXXINITY ANNOUNCES FIRST SUBJECTS DOSED IN PHASE 1
CLINICAL
TRIAL OF UB-313 FOR PREVENTIVE TREATMENT OF MIGRAINE
Source text for Eikon: ID:nGNX1RCbLb
Further company coverage: VAXX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vaxxinity
See all newsU.S. STOCKS ON THE MOVE-EV stocks, Salesforce, Verizon
Brief: Vaxxinity Announces Intention To Voluntarily Delist And Deregister Its Class A Common Stock
Brief: Vaxxinity Announces Intention To Voluntarily Delist And Deregister Its Class A Common Stock
Brief: Vaxxinity Q4 Net Income USD -11.392 Million
Vaxxinity Inc expected to post a loss of 10 cents a share - Earnings Preview